Short-term health plans expansion upheld in court

The Trump administration’s expansion of short-term limited-duration health plans has held up in court after a legal challenge.

The plans, which are not required to comply with Affordable Care Act standards, were expanded by the Trump administration in August 2018. Democrats in Congress, who have called these plans junk insurance because they do not offer comprehensive coverage, attempted to overturn the expansion in October 2018, but failed.

Now, the plans, which were extended from 3 months to 36 months of allowable coverage, can continue, according to U.S. District Judge Richard Leon.

Short-term limited-duration plans were defined under the ACA by the Obama administration as temporary coverage for those who were between insurance coverage, such as students or those switching jobs. Since then, HHS has promoted these plans as an alternative to ACA plans in the marketplace as a more affordable option.

However, the plans do not meet ACA requirements, which means they do not have to cover pre-existing conditions or have limits on out-of-pocket expenses. According to Judge Leon, HHS does have the authority to change the limits of the duration of these plans, court records revealed.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.